Real time identification of drug-induced liver injury (DILI) through daily screening of ALT results: A prospective pilot cohort study

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  M'Kada, Helmi ^a   Perazzo, Hugo ^a   Munteanu, Mona ^b   Ngo, Yen ^b   Ramanujam, Nittia ^a   Fautrel, Bruno ^c   Imbert Bismut, Françoise ^a   Ratziu, Vlad ^a   Schuppe Koistinen, Ina ^d   Leblond, Véronique ^c   Delattre, Jean Yves ^c   Samson, Yves ^c   Caen, Olivier Lyon ^e   Bricaire, François ^f   Khayat, David ^g   Pierrot Deseilligny, Charles ^h   Herson, Serge ⁱ   Amoura, Zahir ^j   Tilleul, Patrick ^c   Deckmyn, Olivier ^b   Coriat, Pierre ^k   Delpech, Vincent Nicolas ^l   Boulogne, Philippe ^m   Bonnefont Rousselot, Dominique ^a,n   Poynard, Thierry ^a   more..

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b Biopredictive   (France)

^c GHPS   (France)

^d ASTRAZENECA R AND D   (Sweden)

^e Neurology 4 GHPS   (France)

^f Infectious Disease Unit GHPS   (France)

^g Oncology Unit GHPS   (France)

^h Neurology 1 GHPS   (France)

ⁱ Internal Medicine 2 GHPS   (France)

^j Internal Medicine 1 GHPS   (France)

^k Intensive Care Anesthesiology GHPS   (France)

^l Administrative Direction GHPS   (France)

^m Information Technology Unit GHPS   (France)

ⁿ FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIINFECTIVE AGENT; PARACETAMOL;

ABDOMINAL PAIN; ACUTE DISEASE; ADULT; ARTICLE; CLINICAL PROTOCOL; COHORT ANALYSIS; DISEASE REGISTRY; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; JAUNDICE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT IDENTIFICATION; PILOT STUDY; PROSPECTIVE STUDY; SCREENING TEST; TOXIC HEPATITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ALGORITHMS; COHORT STUDIES; DRUG-INDUCED LIVER INJURY; FEMALE; GASTROENTEROLOGY; HUMANS; MALE; MIDDLE AGED; NECROSIS; ODDS RATIO; PILOT PROJECTS; PROSPECTIVE STUDIES;

EID: 84865050490     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042418     Document Type: Article

References (22)

1. Lazarou J, Pomeranz BH, Corey PN, (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279: 1200-1205.
2. Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, et al. (2009) Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One 4: e4439.
3. Verma S, Kaplowitz N, (2009) Diagnosis, management and prevention of drug-induced liver injury. Gut 58: 1555-1564.
4. Meier Y, Cavallaro M, Roos M, Pauli-Magnus C, Folkers G, et al. (2005) Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmaco l61: 135-143.
5. Watkins PB, Seligman PJ, Pears JS, Avigan MI, Senior JR, (2008) Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology 48: 1680-1689.
6. Faster Development of Safer Medicines through Translational Safety Biomarkers (SAFE-T consortium). http://www.imi-safe-t.eu/SAFE-T (Accessed December 28, 2011).
7. M'Kada H, Munteanu M, Perazzo H, Ngo Y, Ramanujam N, et al. (2011) What are the best reference values for a normal serum alanine transaminase activity (ALT)? Impact on the presumed prevalence of drug induced liver injury (DILI). Regul Toxicol Pharmacol 60: 290-295.
8. Matheis K, Laurie D, Andriamandroso C, Arber N, Badimon L, et al. (2011) A generic operational strategy to qualify translational safety biomarkers. Drug Discov Today 16: 600-608.
9. Ozer JS, Chetty R, Kenna G, Koppiker N, Karamjeet P, et al. (2010) Recommendations to qualify biomarker candidates of drug-induced liver injury. Biomark Med 4: 475-483.
10. Ozer JS, Chetty R, Kenna G, Palandra J, Zhang Y, et al. (2010) Enhancing the utility of alanine aminotransferase as a reference standard biomarker for drug-induced liver injury. Regul Toxicol Pharmacol 56: 237-246.
11. Piton A, Poynard T, Imbert-Bismut F, Khalil L, Delattre J, et al. (1998) Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. Hepatology 27: 1213-1219.
12. Benichou C, Danan G, Flahault A, (1993) Causality assessment of adverse reactions to drugs-II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 46: 1331-1336.
13. Carey EJ, Vargas HE, Douglas DD, Balan V, Byrne TJ, et al. (2008) Inpatient admissions for drug-induced liver injury: results from a single center. Dig Dis Sci 53: 1977-1982.
14. Devarbhavi H, Dierkhising R, Kremers WK, Sandeep MS, Karanth D, et al. (2010) Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. Am J Gastroenterol 105: 2396-2404.
15. Bagheri H, Michel F, Lapeyre-Mestre M, Lagier E, Cambus JP, et al. (2000) Detection and incidence of drug-induced liver injuries in hospital: a prospective analysis from laboratory signals. Br J Clin Pharmacol 50: 479-484.
16. Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, et al. (1997) The costs of adverse drug events in hospitalized patients. JAMA 277: 307-11.
17. Moore N, Lecointre D, Noblet C, Mabille M, (1998) Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol 45: 301-8.
18. Pirmohamed M, James S, Meakin S, Green C, Scott AK, et al. (2004) Adverse drug reactions as a cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329: 15-19.
19. Nebeker JR, Yarnold PR, Soltysik RC, Sauer BC, Sims SA, et al. (2007) Developing indicators of inpatient drug events through nonlinear analysis using administrative data. Medical Care 45: 81-88.
20. Stausberg J, Hasford J, (2011) Drug-related admissions and hospital-acquired adverse drug events in Germany: a longitudinal analysis from 2003 to 2007 of ICD-10-coded routine data. BMC Health Serv Res 11: 134.
21. Bader T, (2012) Yes! Statins can be given to liver patients. J Hepatol 56: 305-307.
22. Lewis JH, Ranard RC, Caruso A, Jackson LK, Mullick F, et al. (1989) Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients. Hepatology 9: 679-685.